Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial

PURPOSE: Recent data suggest that the glutamatergic system is important in the proliferation and migration of glioblastoma. Talampanel is a well-tolerated, oral α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blocker that could be beneficial in this disease. PATIENTS AND METHODS...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Grossman, Stuart A., Ye, Xiaobu, Chamberlain, Marc, Mikkelsen, Tom, Batchelor, Tracy, Desideri, Serena, Piantadosi, Steven, Fisher, Joy, Fine, Howard A.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2009
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2734427/
https://ncbi.nlm.nih.gov/pubmed/19636006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6895
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires